Contribution of adenylyl cyclase modulation of pre- and postsynaptic GABA neurotransmission to morphine antinociception and tolerance

Neuropsychopharmacology

Volumn 39, Issue 9, 2014, Pages 2142-2152

  Bobeck, Erin N ^a   Chen, Qiliang ^b   Morgan, Michael M ^a   Ingram, Susan L ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 6 (3 DIMETHYLAMINOPROPIONYL)FORSKOLIN; 9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE; BICUCULLINE; MORPHINE SULFATE; SODIUM CHLORIDE; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 9-(TETRAHYDRO-2-FURYL)-ADENINE; ADENINE; ENZYME ACTIVATOR; ENZYME INHIBITOR; FORSKOLIN; MORPHINE; NARCOTIC ANALGESIC AGENT;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELECTROPHYSIOLOGICAL PROCEDURES; MALE; MICROINJECTION; MORPHINE TOLERANCE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; SYNAPTOSOME; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG TOLERANCE; ENZYMOLOGY; INHIBITORY POSTSYNAPTIC POTENTIAL; METABOLISM; MINIATURE ENDPLATE POTENTIAL; NOCICEPTION; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION;

ADENINE; ADENYLATE CYCLASE; ANALGESICS, OPIOID; ANIMALS; BICUCULLINE; COLFORSIN; DRUG TOLERANCE; ENZYME ACTIVATORS; ENZYME INHIBITORS; GABA-A RECEPTOR ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; INHIBITORY POSTSYNAPTIC POTENTIALS; MALE; MINIATURE POSTSYNAPTIC POTENTIALS; MORPHINE; NOCICEPTION; PRESYNAPTIC TERMINALS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; SYNAPTIC TRANSMISSION;

EID: 84904469528     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.62     Document Type: Article

References (49)

1. Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z (1996). Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma. J Biol Chem 271: 21309-21315.
2. Bagley EE, Gerke MB, Vaughan CW, Hack SP, Christie MJ (2005). GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal. Neuron 45: 433-445.
3. Bagley EE, Hacker J, Chefer VI, Mallet C, McNally GP, Chieng BC et al (2011). Drug-induced GABA transporter currents enhance GABA release to induce opioid withdrawal behaviors. Nat Neurosci 14: 1548-1554.
4. Bobeck EN, Haseman RA, Hong D, Ingram SL, Morgan MM (2012). Differential development of antinociceptive tolerance to morphine and fentanyl is not linked to efficacy in the ventrolateral periaqueductal gray of the rat. J Pain 13: 799-807.
5. Bobeck EN, McNeal AL, Morgan MM (2009). Drug dependent sexdifferences in periaqueducatal gray mediated antinociception in the rat. Pain 147: 210-216.
6. Chen G, Kittler JT, Moss SJ, Yan Z (2006). Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. J Neurosci 26: 2513-2521.
7. Commons KG, Aicher SA, Kow LM, Pfaff DW (2000). Presynaptic and postsynaptic relations of mu-opioid receptors to gammaaminobutyric acid-immunoreactive and medullary-projecting periaqueductal gray neurons. J Comp Neurol 419: 532-542.
8. Dighe SV, Madia PA, Sirohi S, Yoburn BC (2009). Continuous morphine produces more tolerance than intermittent or acute treatment. Pharmacol Biochem Behav 92: 537-542.
9. Fields HL, Basbaum AI, Heinricher MM (2005). Central nervous system mechanisms of pain modulation. In: McMahon S, Koltzenburg M (Eds.). Textbook of Pain, 5th ed. Elsevier Health Sciences: Burlington, Massachusetts, USA, 125-142.
10. Fields HL, Vanegas H, Hentall ID, Zorman G (1983). Evidence that disinhibition of brain stem neurones contributes to morphine analgesia. Nature 306: 684-686.
11. Fyfe LW, Cleary DR, Macey TA, Morgan MM, Ingram SL (2010). Tolerance to the antinociceptive effect of morphine in the absence of short-term presynaptic desensitization in rat periaqueductal gray neurons. J Pharmacol Exp Ther 335: 674-680.
12. Gabra BH, Bailey CP, Kelly E, Smith FL, Henderson G, Dewey WL (2008). Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice. Brain Res 1217: 70-77.
13. Garzon J, Rodriguez-Munoz M, Sanchez-Blazquez P (2008). Do pharmacological approaches that prevent opioid tolerance target different elements in the same regulatory machinery? Curr Drug Abuse Rev 1: 222-238.
14. Gintzler AR, Chakrabarti S (2008). The ambiguities of opioid tolerance mechanisms: barriers to pain therapeutics or new pain therapeutic possibilities. J Pharmacol Exp Ther 325: 709-713.
15. Glykys J, Mody I (2007). The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus. J Physiol 582: 1163-1178.
16. Hack SP, Vaughan CW, Christie MJ (2003). Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro. Neuropharmacology 45: 575-584.
17. Heinricher MM, Ingram SL (2008). The brainstem and nociceptive modulation. In: The Senses: A Comprehensive Reference. Academic Press: Elsevier: London, pp 593-626.
18. Herman MA, Gillis RA, Vicini S, Dretchen KL, Sahibzada N (2012). Tonic GABAA receptor conductance in medial subnucleus of the tractus solitarius neurons is inhibited by activation of mu-opioid receptors. J Neurophysiol 107: 1022-1031.
19. Herring D, Huang R, Singh M, Dillon GH, Leidenheimer NJ (2005). PKC modulation of GABAA receptor endocytosis and function is inhibited by mutation of a dileucine motif within the receptor beta 2 subunit. Neuropharmacology 48: 181-194.
20. Ingram SL, Macey TA, Fossum EN, Morgan MM (2008). Tolerance to repeated morphine administration is associated with increased potency of opioid agonists. Neuropsychopharmacology 33: 2494-2504.
21. Ingram SL, Vaughan CW, Bagley EE, Connor M, Christie MJ (1998). Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. J Neurosci 18: 10269-10276.
22. Jacquet YF, Lajtha A (1974). Paradoxical effects after microinjection of morphine in the periaqueductal gray matter in the rat. Science 185: 1055-1057.
23. Jolas T, Nestler EJ, Aghajanian GK (2000). Chronic morphine increases GABA tone on serotonergic neurons of the dorsal raphe nucleus: association with an up-regulation of the cyclic AMP pathway. Neuroscience 95: 433-443.
24. Lane DA, Patel PA, Morgan MM (2005). Evidence for an intrinsic mechanism of antinociceptive tolerance within the ventrolateral periaqueductal gray of rats. Neuroscience 135: 227-234.
25. Li S, Lee ML, Bruchas MR, Chan GC, Storm DR, Chavkin C (2006). Calmodulin-stimulated adenylyl cyclase gene deletion affects morphine responses. Mol Pharmacol 70: 1742-1749.
26. Llorente J, Withey S, Rivero G, Cunningham M, Cooke A, Saxena K et al (2013). Ethanol reversal of cellular tolerance to morphine in rat locus coeruleus neurons. Mol Pharmacol 84: 252-260.
27. Ma J, Pan ZZ (2006). Contribution of brainstem GABA(A) synaptic transmission to morphine analgesic tolerance. Pain 122: 163-173.
28. Madhavan A, He L, Stuber GD, Bonci A, Whistler JL (2010). Microopioid receptor endocytosis prevents adaptations in ventral tegmental area GABA transmission induced during naloxoneprecipitated morphine withdrawal. J Neurosci 30: 3276-3286.
29. Meye FJ, van Zessen R, Smidt MP, Adan RA, Ramakers GM (2012). Morphine withdrawal enhances constitutive mu-opioid receptor activity in the ventral tegmental area. J Neurosci 32: 16120-16128.
30. Meyer PJ, Fossum EN, Ingram SL, Morgan MM (2007). Analgesic tolerance to microinjection of the micro-opioid agonist DAMGO into the ventrolateral periaqueductal gray. Neuropharmacology 52: 1580-1585.
31. Mody I, Pearce RA (2004). Diversity of inhibitory neurotransmission through GABA(A) receptors. Trends Neurosci 27: 569-575.
32. Morgan MM, Clayton CC, Boyer-Quick JS (2005). Differential susceptibility of the PAG and RVM to tolerance to the antinociceptive effect of morphine in the rat. Pain 113: 91-98.
33. Morgan MM, Clayton CC, Lane DA (2003). Behavioral evidence linking opioid-sensitive GABAergic neurons in the ventrolateral periaqueductal gray to morphine tolerance. Neuroscience 118: 227-232.
34. Morgan MM, Fossum EN, Levine CS, Ingram SL (2006). Antinociceptive tolerance revealed by cumulative intracranial microinjections of morphine into the periaqueductal gray in the rat. Pharmacol Biochem Behav 85: 214-219.
35. Morgan MM, Whittier KL, Hegarty DM, Aicher SA (2008). Periaqueductal gray neurons project to spinally projecting GABAergic neurons in the rostral ventromedial medulla. Pain 140: 376-386.
36. Moss SJ, Smart TG, Blackstone CD, Huganir RL (1992). Functional modulation of GABAA receptors by cAMP-dependent protein phosphorylation. Science 257: 661-665.
37. Nowoczyn M, Marie N, Coulbault L, Hervault M, Davis A, Hanouz JL et al (2013). Remifentanil produces cross-desensitization and tolerance with morphine on the mu-opioid receptor. Neuropharmacology 73: 368-379.
38. Osborne PB, Vaughan CW, Wilson HI, Christie MJ (1996). Opioid inhibition of rat periaqueductal grey neurones with identified projections to rostral ventromedial medulla in vitro. J Physiol 490(Pt 2): 383-389.
39. Porter NM, Twyman RE, Uhler MD, Macdonald RL (1990). Cyclic AMP-dependent protein kinase decreases GABAA receptor current in mouse spinal neurons. Neuron 5: 789-796.
40. Punch LJ, Self DW, Nestler EJ, Taylor JR (1997). Opposite modulation of opiate withdrawal behaviors on microinfusion of a protein kinase A inhibitor versus activator into the locus coeruleus or periaqueductal gray. J Neurosci 17: 8520-8527.
41. Richerson GB, Wu Y (2003). Dynamic equilibrium of neurotransmitter transporters: not just for reuptake anymore. J Neurophysiol 90: 1363-1374.
42. Sharma SK, Klee WA, Nirenberg M (1975). Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 72: 3092-3096.
43. Shoblock JR, Maidment NT (2006). Constitutively active micro opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphine-dependent mice. Neuropsychopharmacology 31: 171-177.
44. Shy M, Chakrabarti S, Gintzler AR (2008). Plasticity of adenylyl cyclase-related signaling sequelae after long-term morphine treatment. Mol Pharmacol 73: 868-879.
45. Tortorici V, Robbins CS, Morgan MM (1999). Tolerance to the antinociceptive effect of morphine microinjections into the ventral but not lateral-dorsal periaqueductal gray of the rat. Behav Neurosci 113: 833-839.
46. Vaughan CW, Ingram SL, Connor MA, Christie MJ (1997). How opioids inhibit GABA-mediated neurotransmission. Nature 390: 611-614.
47. Wang L, Gintzler AR (1995). Morphine tolerance and physical dependence: reversal of opioid inhibition to enhancement of cyclic AMP formation. J Neurochem 64: 1102-1106.
48. Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S et al (2013). Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65: 223-254.
49. Zhao H, Loh HH, Law PY (2006). Adenylyl cyclase superactivation induced by long-term treatment with opioid agonist is dependent on receptor localized within lipid rafts and is independent of receptor internalization. Mol Pharmacol 69: 1421-1432.